Table 1 Basic characteristics of enrolled studies
Study | No. | Gender (n) | Median age (year) | Histology (n) | Treatment | ||
|---|---|---|---|---|---|---|---|
| Â | Â | Male | Female | Â | WHO IV | WHO III | Â |
Chen [15] | 21 | 11 | 10 | 58 | 17 | 4 | Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every other week |
Vredenburgh[16] | 35 | 22 | 13 | 48 | 35 | 0 | Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) Q14d, beva (15 mg/kg) Q21d + irino (340 mg/m2 for EIAED, 125 mg/m2 for non-EIAED) on days 1,8,22, and 29, on a 6-week cycle |
Bokstein [17] | 20 | 14 | 6 | 56 | 17 | 3 | Beva (5 mg/kg) + irino (125 mg/m2) every other week |
Guiu [18] | 77 | 50 | 27 | 52 | 49 | 28 | Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) |
Ali [19] | 13 | 7 | 6 | 53 | 13 | 0 | Beva (5 mg/m2) every 2 weeks + irino (125 mg/m2) every week for 3 weeks with 1 week off; beva (10 mg/m2) + irino (125-250 mg/m2) every 2 weeks |
Desjardins [20] | 33 | 22 | 11 | 43 | 0 | 33 | Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) Q14d, beva (15 mg/kg) Q21d + irino (340 mg/m2 for EIAED, 125 mg/m2 for non-EIAED) on days 1,8,22, and 29, on a 6-week cycle |
Kang [21] | 27 | NR | NR | 46 | 12 | 15 | Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) on days 1 and 15 every 28 days |
Poulsen [22] | 52 | 34 | 18 | 46 | 28 | 24 | Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every 2 weeks |
Zuniga cohort A [23] | 14 | 9 | 5 | 51 | 0 | 14 | Beva (10 mg/kg) IV on days 1,15,29 for each cycle; irino (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every 2 weeks, on a 6-week cycle |
Zuniga cohort B [23] | 37 | 24 | 13 | 53 | 37 | 0 | Beva (10 mg/kg) IV on days 1,15,29 for each cycle; irino (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every 2 weeks, on a 6-week cycle |
Friedman [24] | 82 | 57 | 25 | 57 | 82 | 0 | Beva (10 mg/kg) + irino (340 mg/m2 for EIAED; 125 mg/m2 for non-EIAED) every 2 weeks |